# US 2021/0275590 A1 · Single-domain antibodies against cd33 and constructs thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0275590 A1
- Document ID: US20210275590A1
- Status: Published application
- Kind: A1
- Application number: 17/274,458
- Filed: 2019-09-10
- Published: 2021-09-09
- Earliest claimed: 2018-09-10
- Assignees: Nanjing Legend Biotech Co., Ltd.
- Applicants: Nanjing Legend Biotech Co., Ltd.
- Inventors: Yafeng ZHANG; Tailan ZHAN; Fei SUN; Jian LIU; Qing ZHANG; Shu WU
- Web page: https://patentgrep.com/patent/US20210275590A1

## CPC

- C07K 16/2803: {against the immunoglobulin superfamily}
- A61K 35/17: Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes (when activated by a specific antigen A61K39/00)
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/31: Chimeric antigen receptors [CAR]
- A61K 40/4202: {Receptors, cell surface antigens or cell surface determinants}
- A61K 40/4204: {Epidermal growth factor receptors [EGFR]}
- A61K 40/421: {Immunoglobulin superfamily}
- A61K 40/4221: {CD20}
- A61K 40/4224: {Molecules with a "CD" designation not provided for elsewhere}
- A61P 35/00: Antineoplastic agents
- C07K 14/7051: {T-cell receptor (TcR)-CD3 complex}
- C07K 14/70578: {NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95 (NGF-receptor C07K14/71, TNF-receptor C07K14/7151)}
- C07K 16/24: against cytokines, lymphokines or interferons
- C07K 16/2851: {against the lectin superfamily, e.g. CD23, CD72}
- C07K 16/2866: {against receptors for cytokines, lymphokines, interferons}
- C12N 5/0636: {T lymphocytes}
- A61K 2039/505: {comprising antibodies}
- A61K 2239/29: Multispecific CARs
- A61K 2239/31: characterized by the route of administration
- A61K 2239/38: characterised by the dose, timing or administration schedule
- A61K 2239/48: Blood cells, e.g. leukemia or lymphoma
- C07K 2317/22: from camelids, e.g. camel, llama or dromedary
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/31: multispecific
- C07K 2317/33: Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/569: Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K 2319/02: containing a signal sequence
- C07K 2319/03: containing a transmembrane segment
- C07K 2319/33: fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
- C12N 2510/00: Genetically modified cells
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present application provides single-domain antibodies targeting CD33 and constructs thereof, including chimeric receptors, immune effector cell engagers and immunoconjugates. Further provided are engineered immune cells (such as T cells) comprising an anti-CD33 chimeric receptor and optionally a second chimeric receptor targeting a second antigen or epitope. Pharmaceutical compositions, kits and methods of treating cancer are also provided.

## Claims

### Claim 1

An anti-CD33 construct comprising a single domain antibody (“sdAb”) moiety that specifically binds to CD33, wherein the sdAb moiety comprises a CDR1 comprising the amino acid sequence of any one of SEQ ID NOs: 4, 11, 18, 25, 32, 39, 46, 53, 60, 67, 74, 81, 88, 95, and 102, or a variant thereof comprising up to about 3 amino acid substitutions in the CDR1; a CDR2 comprising the amino acid sequence of any one of SEQ ID NOs: 6, 13, 20, 27, 34, 41, 48, 55, 62, 69, 76, 83, 90, 97, and 104, or a variant thereof comprising up to about 3 amino acid substitutions in the CDR2; and a CDR3 comprising the amino acid sequence of any one of SEQ ID NOs: 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, 78, 85, 92, 99, and 106, or a variant thereof comprising up to about 3 amino acid substitutions in the CDR3.

### Claim 2

(canceled)

### Claim 3 (depends on 1)

The anti-CD33 construct of claim 1, wherein the sdAb moiety comprises:
(1) a CDR1 comprising the amino acid sequence of SEQ ID NO: 4, a CDR2 comprising the amino acid sequence of SEQ ID NO: 6, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 8;
(2) a CDR1 comprising the amino acid sequence of SEQ ID NO: 11, a CDR2 comprising the amino acid sequence of SEQ ID NO: 13, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 15;
(3) a CDR1 comprising the amino acid sequence of SEQ ID NO: 18, a CDR2 comprising the amino acid sequence of SEQ ID NO: 20, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 22;
(4) a CDR1 comprising the amino acid sequence of SEQ ID NO: 25, a CDR2 comprising the amino acid sequence of SEQ ID NO: 27, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 29;
(5) a CDR1 comprising the amino acid sequence of SEQ ID NO: 32, a CDR2 comprising the amino acid sequence of SEQ ID NO: 34, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 36;
(6) a CDR1 comprising the amino acid sequence of SEQ ID NO: 39, a CDR2 comprising the amino acid sequence of SEQ ID NO: 41, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 43;
(7) a CDR1 comprising the amino acid sequence of SEQ ID NO: 46, a CDR2 comprising the amino acid sequence of SEQ ID NO: 48, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 50;
(8) a CDR1 comprising the amino acid sequence of SEQ ID NO: 53, a CDR2 comprising the amino acid sequence of SEQ ID NO: 55, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 57;
(9) a CDR1 comprising the amino acid sequence of SEQ ID NO: 60, a CDR2 comprising the amino acid sequence of SEQ ID NO: 62, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 64;
(10) a CDR1 comprising the amino acid sequence of SEQ ID NO: 67, a CDR2 comprising the amino acid sequence of SEQ ID NO: 69, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 71;
(11) a CDR1 comprising the amino acid sequence of SEQ ID NO: 74, a CDR2 comprising the amino acid sequence of SEQ ID NO: 76, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 78;
(12) a CDR1 comprising the amino acid sequence of SEQ ID NO: 81, a CDR2 comprising the amino acid sequence of SEQ ID NO: 83, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 85;
(13) a CDR1 comprising the amino acid sequence of SEQ ID NO: 88, a CDR2 comprising the amino acid sequence of SEQ ID NO: 90, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 92;
(14) a CDR1 comprising the amino acid sequence of SEQ ID NO: 95, a CDR2 comprising the amino acid sequence of SEQ ID NO: 97, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 99; or
(15) a CDR1 comprising the amino acid sequence of SEQ ID NO: 102, a CDR2 comprising the amino acid sequence of SEQ ID NO: 104, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 106.

### Claim 4

(canceled)

### Claim 5 (depends on 1)

The anti-CD33 construct of claim 1, wherein the sdAb moiety comprises an amino acid sequence having at least about 95% sequence identity to the amino acid sequence of any one of SEQ ID NOs: 108-122.

### Claim 6

(canceled)

### Claim 7 (depends on 1)

The anti-CD33 construct of claim 1, wherein the anti-CD33 construct comprises an extracellular domain comprising the sdAb moiety, a transmembrane domain, and an intracellular signaling domain comprising a primary intracellular signaling sequence of an immune effector cell.

### Claim 8

(canceled)

### Claim 9 (depends on 7)

The anti-CD33 construct of claim 7, wherein the intracellular signaling domain further comprises an intracellular co-stimulatory sequence.

### Claim 10

(canceled)

### Claim 11 (depends on 1)

The anti-CD33 construct of claim 1, wherein the anti-CD33 construct comprises an extracellular domain comprising the sdAb moiety, a transmembrane domain, and an intracellular signaling domain comprising an intracellular co-stimulatory sequence.

### Claim 12

(canceled)

### Claim 13 (depends on 7)

The anti-CD33 construct of claim 7, wherein the anti-CD33 sdAb moiety comprises: (1) a CDR1 comprising the amino acid sequence of SEQ ID NO: 18, a CDR2 comprising the amino acid sequence of SEQ ID NO: 20, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 22, or (2) a CDR1 comprising the amino acid sequence of SEQ ID NO: 95, a CDR2 comprising the amino acid sequence of SEQ ID NO: 97, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 99.

### Claim 14 (depends on 7)

The anti-CD33 construct of claim 7, wherein the extracellular domain of the anti-CD33 construct further comprises a second binding moiety that specifically binds to a second antigen or epitope.

### Claim 15

(canceled)

### Claim 16 (depends on 14)

The anti-CD33 construct of claim 14, wherein the second binding moiety is an sdAb or scFv that specifically binds to CLL1 or CD123.

### Claim 17 (depends on 14)

The anti-CD33 construct of claim 14, wherein the second binding moiety is an extracellular domain of NKG2D.

### Claim 18 (depends on 14)

The anti-CD33 construct of claim 14, wherein the extracellular domain comprises: (1) the anti-CD33 sdAb moiety and an anti-CLL1 sdAb moiety, wherein the anti-CD33 sdAb moiety comprises: a CDR1 comprising the amino acid sequence of SEQ ID NO: 11, a CDR2 comprising the amino acid sequence of SEQ ID NO: 13, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 15, or (2) a CDR1 comprising the amino acid sequence of SEQ ID NO: 18, a CDR2 comprising the amino acid sequence of SEQ ID NO: 20 and a CDR3 comprising the amino acid sequence of SEQ ID NO: 22; and wherein the anti-CLL1 sdAb moiety comprises: a CDR1 comprising the amino acid sequence of SEQ ID NO: 189, a CDR2 comprising the amino acid sequence of SEQ ID NO: 191, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 193.

### Claim 19 (depends on 1)

The anti-CD33 construct of claim 1, wherein the anti-CD33 construct comprises the amino acid sequence of any one of SEQ ID NOs: 108-122, 155-169, 170-181 and 183-185.

### Claim 20 (depends on 1)

A nucleic acid encoding the anti-CD33 construct of claim 1.

### Claim 21 (depends on 1)

An engineered immune cell comprising the anti-CD33 construct of claim 1.

### Claim 22 (depends on 21)

The engineered immune cell of claim 21, further comprising a second chimeric receptor.

### Claim at position 23

23-28. (canceled)

### Claim 29 (depends on 22)

The engineered immune cell of claim 22, wherein the anti-CD33 construct is a first chimeric receptor, wherein: (a) the first chimeric receptor comprises an extracellular domain comprising the anti-CD33 sdAb, a transmembrane, and an intracellular signaling domain, wherein the anti-CD33 sdAb comprises: (1) a CDR1 comprising the amino acid sequence of SEQ ID NO: 25, a CDR2 comprising the amino acid sequence of SEQ ID NO: 27, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 29; (2) a CDR1 comprising the amino acid sequence of SEQ ID NO: 53, a CDR2 comprising the amino acid sequence of SEQ ID NO: 55, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 57; or (3) a CDR1 comprising the amino acid sequence of SEQ ID NO: 95, a CDR2 comprising the amino acid sequence of SEQ ID NO: 97, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 99; and (b) the second chimeric receptor comprises an extracellular domain comprising an anti-CLL1 sdAb, a transmembrane domain, and an intracellular signaling domain, wherein the anti-CLL1 sdAb comprises: (1) a CDR1 comprising the amino acid sequence of SEQ ID NO: 196, a CDR2 comprising the amino acid sequence of SEQ ID NO: 198, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 200; or (2) a CDR1 comprising the amino acid sequence of SEQ ID NO: 203, a CDR2 comprising the amino acid sequence of SEQ ID NO: 205, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 207.

### Claim 30 (depends on 21)

The engineered immune cell of claim 21, wherein the immune cell is a T cell.

### Claim at position 26

31-34. (canceled)

### Claim 35 (depends on 1)

The anti-CD33 construct of claim 1, wherein the anti-CD33 construct is a multispecific molecule.

### Claim 36 (depends on 35)

The anti-CD33 construct of claim 35, wherein the anti-CD33 construct comprises the sdAb moiety linked to a second binding moiety that specifically binds to a second antigen or epitope.

### Claim at position 29

37-40. (canceled)

### Claim 41 (depends on 1)

The anti-CD33 construct of claim 1, wherein the anti-CD33 construct is an immunoconjugate comprising the sdAb moiety and an effector molecule.

### Claim at position 31

42-44. (canceled)

### Claim 45 (depends on 1)

A pharmaceutical composition comprising the anti-CD33 construct of claim 1.

### Claim 46 (depends on 1)

A method of treating an individual having a cancer, comprising administering to the individual an effective amount of the anti-CD33 construct of claim 1.

### Claim 47

(canceled)
